Skip to main content

Table 3 Antimicrobial susceptibility of isolates

From: Evaluating molecular epidemiology of carbapenem non-susceptible Klebsiella pneumoniae isolates with MLST, MALDI-TOF MS, PFGE

Antibiotics

Susceptible (%)

Intermediate (%)

Resistant (%)

Amikasin (AK)

12 (37.6)

14 (43.7)

6 (18.7)

Gentamicin (GN)

25 (78.1)

0

7 (21.9)

Tobramycin (TOB)

5 (15.6)

0

27 (84.4)

Ciprofloxacin (CIP)

2 (6.3)

0

30 (93.7)

Levofloxacin (LEV)

2 (6.3)

0

30 (93.7)

Ceftazidime (CAZ)

0

0

32 (100.0)

Imipenem (IPM)

0

7 (21.8)

25 (78.2)

Meropenem (MEM)

0

0

32 (100.0)

Cefepime (FEP)

0

0

32 (100.0)

Piperacillin/tazobactam (TZP)

0

0

32 (100.0)

Trimethoprim/sulfametoxazole (SXT)

13 (40.6)

0

19 (59.4)

Colistin (COL)

19 (59.3)

0

13 (40.7)